<DOC>
	<DOC>NCT00111644</DOC>
	<brief_summary>This study will assess the efficacy and safety of intravenous beta-lactam, in comparison with ceftriaxone, in hospitalized patients with community-acquired pneumonia not caused by Legionella. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia, Bacterial</mesh_term>
	<mesh_term>Ceftriaxone</mesh_term>
	<mesh_term>beta-Lactams</mesh_term>
	<mesh_term>Lactams</mesh_term>
	<criteria>male or female patients at least 18 years of age; hospitalization with communityacquired pneumonia or development of pneumonia within 48 hours of being hospitalized for another reason; fever; new or increased productive cough; chest pain, shortness of breath, or rapid breathing. requiring intubation or ventilation; nursing home or extended care within 60 days before study; concomitant bacterial infection requiring antibiotics; longterm immunosuppressive therapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>